83 related articles for article (PubMed ID: 3226724)
1. Sequence determinants of c-myc mRNA turn-over: influence of 3' and 5' non-coding regions.
Bonnieu A; Piechaczyk M; Marty L; Cuny M; Blanchard JM; Fort P; Jeanteur P
Oncogene Res; 1988 Sep; 3(2):155-66. PubMed ID: 3226724
[TBL] [Abstract][Full Text] [Related]
2. Altered myc gene transcription and intron-induced stabilization of myc RNAs in two mouse plasmacytomas.
Bauer SR; Piechaczyk M; Nordan RP; Owens JD; Nepveu A; Marcu KB; Mushinski JF
Oncogene; 1989 May; 4(5):615-23. PubMed ID: 2657576
[TBL] [Abstract][Full Text] [Related]
3. Altered c-myc RNA metabolism in Burkitt's lymphomas and mouse plasmacytomas.
Piechaczyk M; Bonnieu A; Eick D; Remmers E; Yang JQ; Marcu K; Jeanteur P; Blanchard JM
Curr Top Microbiol Immunol; 1986; 132():331-8. PubMed ID: 3024921
[No Abstract] [Full Text] [Related]
4. Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations.
Müller JR; Janz S; Potter M
Cancer Res; 1995 Nov; 55(21):5012-8. PubMed ID: 7585544
[TBL] [Abstract][Full Text] [Related]
5. The block of elongation in c-myc exon 1 is abolished in Burkitt's lymphoma cell lines with variant translocation.
Eick D; Polack A; Kofler E; Bornkamm GW
Oncogene; 1988 Oct; 3(4):397-403. PubMed ID: 3078949
[TBL] [Abstract][Full Text] [Related]
6. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
7. AUUUA motifs are dispensable for rapid degradation of the mouse c-myc RNA.
Bonnieu A; Roux P; Marty L; Jeanteur P; Piechaczyk M
Oncogene; 1990 Oct; 5(10):1585-8. PubMed ID: 2250915
[TBL] [Abstract][Full Text] [Related]
8. Aberrant class switching juxtaposes c-myc with a middle repetitive element (LINE) and an IgH intron in two spontaneously arising rat immunocytomas.
Pear WS; Nelson SF; Axelson H; Wahlström G; Bazin H; Klein G; Sümegi J
Oncogene; 1988 May; 2(5):499-507. PubMed ID: 3131719
[TBL] [Abstract][Full Text] [Related]
9. c-fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation.
Veyrune JL; Carillo S; Vié A; Blanchard JM
Oncogene; 1995 Nov; 11(10):2127-34. PubMed ID: 7478533
[TBL] [Abstract][Full Text] [Related]
10. What determines the instability of c-myc proto-oncogene mRNA?
Laird-Offringa IA
Bioessays; 1992 Feb; 14(2):119-24. PubMed ID: 1575711
[TBL] [Abstract][Full Text] [Related]
11. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Bhatia K; Huppi K; Spangler G; Siwarski D; Iyer R; Magrath I
Nat Genet; 1993 Sep; 5(1):56-61. PubMed ID: 8220424
[TBL] [Abstract][Full Text] [Related]
12. Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives.
Eick D; Piechaczyk M; Henglein B; Blanchard JM; Traub B; Kofler E; Wiest S; Lenoir GM; Bornkamm GW
EMBO J; 1985 Dec; 4(13B):3717-25. PubMed ID: 3004968
[TBL] [Abstract][Full Text] [Related]
13. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
14. Posttranscriptional mechanisms are responsible for accumulation of truncated c-myc RNAs in murine plasma cell tumors.
Piechaczyk M; Yang JQ; Blanchard JM; Jeanteur P; Marcu KB
Cell; 1985 Sep; 42(2):589-97. PubMed ID: 2411425
[TBL] [Abstract][Full Text] [Related]
15. The 5' and 3' non-coding sequences of the c-myc gene, required in vitro for its post-transcriptional regulation, are dispensable in vivo.
Morello D; Lavenu A; Pournin S; Babinet C
Oncogene; 1993 Jul; 8(7):1921-9. PubMed ID: 8510935
[TBL] [Abstract][Full Text] [Related]
16. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
17. Role of first exon/intron sequences in the regulation of myc family oncogenic potency.
Xu L; Wallen R; Patel V; DePinho RA
Oncogene; 1993 Sep; 8(9):2547-53. PubMed ID: 8361763
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.
Boffa LC; Cutrona G; Cilli M; Matis S; Damonte G; Mariani MR; Millo E; Moroni M; Roncella S; Fedeli F; Ferrarini M
Cancer Gene Ther; 2007 Feb; 14(2):220-6. PubMed ID: 17053816
[TBL] [Abstract][Full Text] [Related]
19. Retroviral enhancer insertion 5' of c-myc in two translocation-negative mouse plasmacytomas upregulates c-myc expression to different extents.
Shaughnessy JD; Owens JD; Wiener F; Hilbert DM; Huppi K; Potter M; Mushinski JF
Oncogene; 1993 Nov; 8(11):3111-21. PubMed ID: 8414513
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activation of the translocated c-myc oncogene in mouse plasmacytomas: similar RNA levels in tumor and proliferating normal cells.
Keath EJ; Kelekar A; Cole MD
Cell; 1984 Jun; 37(2):521-8. PubMed ID: 6327072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
